But like all supplements, results vary
Here is what the clinical evidence actually shows: Semaglutide (Wegovy / Ozempic) Semaglutide activates GLP-1 receptors only
Heimbrger SM, Bergmann NC, Augustin R, Gasbjerg LS, Christensen MB, Knop FK (2020) Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Lowering the insulin dose might be needed, but reducing the dose too much can lead to elevated blood ketones and even DKA
They are not regulated and tested like prescription medications, meaning they may not be effective, could have unknown side effects, or contain hidden (and potentially dangerous) ingredients
FDA approval was based on the SOUL cardiovascular outcomes trial (CVOT) that demonstrated a 14% relative reduction in risk of MACE in patients treated with Rybelsus 14 mg orally once daily for approximately 5 years compared to those who received placebo